The uncertainty of MS affects everyone with a diagnosis; uncertainty about what tomorrow might hold. But it also demands urgency to bring an end to this disease for everyone – forever.
Prevention for future generations must become a reality. Without it, we haven’t delivered a complete solution to people with MS.
Ending MS means no one will ever get this disease again. That means we need to find the cause of MS, what triggers it, and what may protect against it. Here’s how:
We aggressively pursue studies to identify all common MS-related genes, because genes make people susceptible to MS – so that we can answer how it is triggered and how it could be prevented
We must better understand what factors in the environment influence whether a person gets MS
We must identify possible infectious triggers for MS
Research News Related to Ending MS
Dec 04, 2013
Researchers in Italy provide preliminary evidence that a vaccine used in some parts of the world to prevent tuberculosis, called Bacille Calmette-Guérin (BCG), may help people who exhibit early signs of possible MS from developing full-blown, definite MS. Additional, larger trials would be needed to determine the safety and effectiveness of this approach.
Nov 05, 2013
The National MS Society has just launched 38 new MS research projects, with multiyear commitments totaling $19.4 million. This commitment is the latest in the Society’s relentless research effort to find solutions for everyone affected by MS.
Oct 17, 2013
Researchers from the Harvard Medical School, Brigham and Women’s Hospital, and Partners Multiple Sclerosis Center, in collaboration with the National Institute of Neurological Disorders and Stroke (a branch of the National Institute of Health, NIH), are recruiting 5,000 subjects who have at least one first-degree relative with a diagnosis of MS. The goal of the study is to identify the genetic, environmental and immune profiles that may increase a person’s risk of developing MS. A first-degree relative could be a parent, sibling, or child of a person with MS, and the study is limited to those between 18 and 50 years of age. The GEMS (Genes and Environment in MS) study is led by primary investigator Philip De Jager, MD, PhD, a Harry Weaver Neuroscience Scholar of the National MS Society. The study is privately funded. Daniel Reich, MD, PhD, is the site principal investigator at NIH.